ATE194493T1 - Verfahren zur behandlung von hyperproliferaktiven gefässerkrankungen unter verwendung von rapamycin, eventuell in kombination mit mykophenolsäure - Google Patents

Verfahren zur behandlung von hyperproliferaktiven gefässerkrankungen unter verwendung von rapamycin, eventuell in kombination mit mykophenolsäure

Info

Publication number: ATE194493T1
Authority: AT; Austria
Prior art keywords: treating; combination; rapamycin; mycophenolic acid; hyperproliferactive
Prior art date: 1992-01-09

Application number

AT93300052T

Other languages

English (en)

Inventor

Randall Ellis Morris

Clare Robert Gregory

Original Assignee

American Home Prod

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-01-09

Filing date

1993-01-06

Publication date

2000-07-15

1993-01-06 Application filed by American Home Prod filed Critical American Home Prod

2000-07-15 Application granted granted Critical

2000-07-15 Publication of ATE194493T1 publication Critical patent/ATE194493T1/de

Links

HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 title abstract 2
229960000951 mycophenolic acid Drugs 0.000 title abstract 2
HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 title abstract 2
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 title abstract 2
229960002930 sirolimus Drugs 0.000 title abstract 2
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title abstract 2
208000019553 vascular disease Diseases 0.000 title abstract 2
241000124008 Mammalia Species 0.000 abstract 1
230000001028 anti-proliverative effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Steroid Compounds (AREA)
Compounds Of Unknown Constitution (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

AT93300052T 1992-01-09 1993-01-06 Verfahren zur behandlung von hyperproliferaktiven gefässerkrankungen unter verwendung von rapamycin, eventuell in kombination mit mykophenolsäure ATE194493T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US81931492A	1992-01-09	1992-01-09

Publications (1)

Publication Number	Publication Date
ATE194493T1 true ATE194493T1 (de)	2000-07-15

Family

ID=25227805

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT93300052T ATE194493T1 (de)	1992-01-09	1993-01-06	Verfahren zur behandlung von hyperproliferaktiven gefässerkrankungen unter verwendung von rapamycin, eventuell in kombination mit mykophenolsäure

Country Status (14)

Country	Link
EP (1)	EP0551182B1 (de)
JP (1)	JP2644955B2 (de)
KR (1)	KR100276142B1 (de)
AT (1)	ATE194493T1 (de)
AU (1)	AU665041B2 (de)
CA (1)	CA2086642C (de)
DE (1)	DE69328981T2 (de)
DK (1)	DK0551182T3 (de)
ES (1)	ES2147740T3 (de)
GR (1)	GR3034479T3 (de)
LV (1)	LV12603B (de)
NZ (1)	NZ245630A (de)
PT (1)	PT551182E (de)
SG (1)	SG47639A1 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5811447A (en)	1993-01-28	1998-09-22	Neorx Corporation	Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en)	1991-09-27	2003-02-04	Neorx Corporation	Therapeutic inhibitor of vascular smooth muscle cells
US5516781A (en) *	1992-01-09	1996-05-14	American Home Products Corporation	Method of treating restenosis with rapamycin
US5283257A (en) *	1992-07-10	1994-02-01	The Board Of Trustees Of The Leland Stanford Junior University	Method of treating hyperproliferative vascular disease
US5981568A (en)	1993-01-28	1999-11-09	Neorx Corporation	Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en)	1993-05-13	2002-12-10	Neorx Corporation	Therapeutic inhibitor of vascular smooth muscle cells
US6663881B2 (en)	1993-01-28	2003-12-16	Neorx Corporation	Therapeutic inhibitor of vascular smooth muscle cells
CA2472404A1 (en)	1993-07-19	1995-02-02	Angiotech Pharmaceuticals, Inc.	Combination of stent and anti-angiogenic factor
CA2175215C (en) *	1993-11-19	2008-06-03	Yat Sun Or	Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
US5527907A (en) *	1993-11-19	1996-06-18	Abbott Laboratories	Macrolide immunomodulators
US5519042A (en) *	1994-01-13	1996-05-21	Hoechst Aktiengesellschaft	Method of treating hyperproliferative vascular disease
US5444072A (en) *	1994-02-18	1995-08-22	Syntex (U.S.A.) Inc.	6-substituted mycophenolic acid and derivatives
US6558798B2 (en)	1995-02-22	2003-05-06	Scimed Life Systems, Inc.	Hydrophilic coating and substrates coated therewith having enhanced durability and lubricity
US5605696A (en) *	1995-03-30	1997-02-25	Advanced Cardiovascular Systems, Inc.	Drug loaded polymeric material and method of manufacture
US5985890A (en)	1995-06-09	1999-11-16	Novartis Ag	Rapamycin derivatives
KR100616020B1 (ko) *	1996-03-27	2007-01-31	노파르티스 아게	맥관장애및이종이식술에서의라파마이신유도체의용도
GB9606452D0 (en) *	1996-03-27	1996-06-05	Sandoz Ltd	Organic compounds
ID18663A (id) *	1996-04-12	1998-04-30	Novartis Ag	Komposisi farmasi berlapis enterik
US6515016B2 (en)	1996-12-02	2003-02-04	Angiotech Pharmaceuticals, Inc.	Composition and methods of paclitaxel for treating psoriasis
US6495579B1 (en)	1996-12-02	2002-12-17	Angiotech Pharmaceuticals, Inc.	Method for treating multiple sclerosis
IT1289815B1 (it)	1996-12-30	1998-10-16	Sorin Biomedica Cardio Spa	Stent per angioplastica e relativo procedimento di produzione
US6273913B1 (en) †	1997-04-18	2001-08-14	Cordis Corporation	Modified stent useful for delivery of drugs along stent strut
US7208011B2 (en)	2001-08-20	2007-04-24	Conor Medsystems, Inc.	Implantable medical device with drug filled holes
US6241762B1 (en)	1998-03-30	2001-06-05	Conor Medsystems, Inc.	Expandable medical device with ductile hinges
US7208010B2 (en)	2000-10-16	2007-04-24	Conor Medsystems, Inc.	Expandable medical device for delivery of beneficial agent
WO1999055396A1 (en)	1998-04-27	1999-11-04	Surmodics, Inc.	Bioactive agent release coating
US6120847A (en) *	1999-01-08	2000-09-19	Scimed Life Systems, Inc.	Surface treatment method for stent coating
US6419692B1 (en)	1999-02-03	2002-07-16	Scimed Life Systems, Inc.	Surface protection method for stents and balloon catheters for drug delivery
US6156373A (en)	1999-05-03	2000-12-05	Scimed Life Systems, Inc.	Medical device coating methods and devices
US6258121B1 (en)	1999-07-02	2001-07-10	Scimed Life Systems, Inc.	Stent coating
US6251136B1 (en)	1999-12-08	2001-06-26	Advanced Cardiovascular Systems, Inc.	Method of layering a three-coated stent using pharmacological and polymeric agents
US6702849B1 (en)	1999-12-13	2004-03-09	Advanced Cardiovascular Systems, Inc.	Method of processing open-celled microcellular polymeric foams with controlled porosity for use as vascular grafts and stent covers
DE60133053T2 (de)	2000-10-16	2009-02-26	Conor Medsystems, Inc., Menlo Park	Ausdehnbare medizinische Vorrichtung zur Abgabe eines nützlichen Agens
DE10115740A1 (de)	2001-03-26	2002-10-02	Ulrich Speck	Zubereitung für die Restenoseprophylaxe
US6613083B2 (en)	2001-05-02	2003-09-02	Eckhard Alt	Stent device and method
US7842083B2 (en)	2001-08-20	2010-11-30	Innovational Holdings, Llc.	Expandable medical device with improved spatial distribution
US7056338B2 (en)	2003-03-28	2006-06-06	Conor Medsystems, Inc.	Therapeutic agent delivery device with controlled therapeutic agent release rates
US7682387B2 (en)	2002-04-24	2010-03-23	Biosensors International Group, Ltd.	Drug-delivery endovascular stent and method for treating restenosis
US6939376B2 (en)	2001-11-05	2005-09-06	Sun Biomedical, Ltd.	Drug-delivery endovascular stent and method for treating restenosis
US7097850B2 (en)	2002-06-18	2006-08-29	Surmodics, Inc.	Bioactive agent release coating and controlled humidity method
DE10244847A1 (de)	2002-09-20	2004-04-01	Ulrich Prof. Dr. Speck	Medizinische Vorrichtung zur Arzneimittelabgabe
ATE538820T1 (de)	2003-02-21	2012-01-15	Sorin Biomedica Cardio Srl	Verfahren zur herstellung eines stents und entsprechender stent
AR045957A1 (es) *	2003-10-03	2005-11-16	Novartis Ag	Composicion farmaceutica y combinacion
US7303758B2 (en)	2004-01-20	2007-12-04	Cordis Corporation	Local vascular delivery of mycophenolic acid in combination with rapamycin to prevent restenosis following vascular injury
JP2007532187A (ja)	2004-04-06	2007-11-15	サーモディクス，インコーポレイティド	生物活性物質のためのコーティング組成物
USD516723S1 (en)	2004-07-06	2006-03-07	Conor Medsystems, Inc.	Stent wall structure
WO2007040249A1 (ja)	2005-10-06	2007-04-12	Kaneka Corporation	生体留置用ステント
US20100063585A1 (en)	2006-07-03	2010-03-11	Hemoteq Ag	Manufacture, method and use of active substance-releasing medical products for permanently keeping blood vessels open
ES2393639T3 (es)	2007-01-21	2012-12-26	Hemoteq Ag	Producto médico para tratar cierres de conductos corporales y prevención de nuevos cierres
US9192697B2 (en)	2007-07-03	2015-11-24	Hemoteq Ag	Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis
US8921642B2 (en)	2008-01-11	2014-12-30	Massachusetts Eye And Ear Infirmary	Conditional-stop dimerizable caspase transgenic animals
EP2944332B1 (de)	2009-07-10	2016-08-17	Boston Scientific Scimed, Inc.	Verwendung von nanokristallen für einen wirkstofffreisetzungsballon
EP2453938B1 (de)	2009-07-17	2015-08-19	Boston Scientific Scimed, Inc.	Nukleierung von wirkstofffreisetzungsballons für verbesserte kristallgrösse und -dichte
EP2611476B1 (de)	2010-09-02	2016-08-10	Boston Scientific Scimed, Inc.	Beschichtungsverfahren für wirkstofffreisetzungsballons mit wärmeinduziertem rewrap-gedächtnis
US8669360B2 (en)	2011-08-05	2014-03-11	Boston Scientific Scimed, Inc.	Methods of converting amorphous drug substance into crystalline form
WO2013028208A1 (en)	2011-08-25	2013-02-28	Boston Scientific Scimed, Inc.	Medical device with crystalline drug coating
JP6278332B2 (ja)	2013-04-22	2018-02-14	スズキ株式会社	変速機の制御装置

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5078999A (en) *	1991-02-22	1992-01-07	American Home Products Corporation	Method of treating systemic lupus erythematosus

1993
- 1993-01-04 CA CA002086642A patent/CA2086642C/en not_active Expired - Lifetime
- 1993-01-06 ES ES93300052T patent/ES2147740T3/es not_active Expired - Lifetime
- 1993-01-06 DE DE69328981T patent/DE69328981T2/de not_active Expired - Lifetime
- 1993-01-06 SG SG1996003304A patent/SG47639A1/en unknown
- 1993-01-06 PT PT93300052T patent/PT551182E/pt unknown
- 1993-01-06 AT AT93300052T patent/ATE194493T1/de active
- 1993-01-06 DK DK93300052T patent/DK0551182T3/da active
- 1993-01-06 EP EP93300052A patent/EP0551182B1/de not_active Expired - Lifetime
- 1993-01-07 AU AU31079/93A patent/AU665041B2/en not_active Expired
- 1993-01-07 NZ NZ245630A patent/NZ245630A/en not_active IP Right Cessation
- 1993-01-08 KR KR1019930000174A patent/KR100276142B1/ko not_active Expired - Lifetime
- 1993-01-08 JP JP5001773A patent/JP2644955B2/ja not_active Expired - Lifetime
2000
- 2000-09-26 GR GR20000402168T patent/GR3034479T3/el unknown
- 2000-10-06 LV LVP-00-134A patent/LV12603B/en unknown

Also Published As

Publication number	Publication date
AU3107993A (en)	1993-07-15
JPH069390A (ja)	1994-01-18
KR100276142B1 (ko)	2001-02-01
SG47639A1 (en)	1998-04-17
NZ245630A (en)	1997-07-27
GR3034479T3 (en)	2000-12-29
AU665041B2 (en)	1995-12-14
DE69328981T2 (de)	2000-11-16
EP0551182A1 (de)	1993-07-14
HK1010332A1 (en)	1999-06-17
ES2147740T3 (es)	2000-10-01
CA2086642C (en)	2004-06-15
LV12603B (en)	2001-04-20
JP2644955B2 (ja)	1997-08-25
CA2086642A1 (en)	1993-07-10
DK0551182T3 (da)	2000-10-09
DE69328981D1 (de)	2000-08-17
PT551182E (pt)	2000-12-29
LV12603A (en)	2001-01-20
KR930016102A (ko)	1993-08-26
EP0551182B1 (de)	2000-07-12

Legal Events

Date	Code	Title	Description
2000-11-15	UEP	Publication of translation of european patent specification

Publication	Publication Date	Title
ATE194493T1 (de)	2000-07-15	Verfahren zur behandlung von hyperproliferaktiven gefässerkrankungen unter verwendung von rapamycin, eventuell in kombination mit mykophenolsäure
DE69524679D1 (de)	2002-01-31	Verwendung Rapamycin zur Herstellung eines Medikaments für die Verbeugung und Behandlung von hyperproliferativen Gefässerkrankheiten, eventuell in Kombination mit Mycophenolsäure
ATE207355T1 (de)	2001-11-15	Behandlung von hyperproliferativen gefässerkrankungen
DE69232565D1 (de)	2002-05-23	Verfahren zur behandlung von lungenerkrankungen mit uridin-triphosphaten
DE69010162D1 (de)	1994-07-28	Zusammensetzung zur Behandlung von Entzündung.
DE3867736D1 (de)	1992-02-27	Methylenphosphonalkylphosphinate, pharmazeutische zubereitungen und verfahren zur behandlung abnormalen kalzium- und phosphat-stoffwechsels.
EP0820467A4 (de)	2001-12-05	Verfahren zur behandlung von augenkrankheiten
ATE147977T1 (de)	1997-02-15	Verwendung von kompetitiven nmda- rezeptorantagonisten zur behandlung der harninkontinenz
DE69929787D1 (de)	2006-04-20	Verfahren zur behandlung von neurologischen erkrankungen mit hilfe der bestimmung des bche genotyps
DE59209268D1 (de)	1998-05-07	Verfahren zur thermochemisch-thermischen behandlung von einsatzstählen
ATE201388T1 (de)	2001-06-15	Verfahren zur verbesserung der biozidaktivität
DE60015791D1 (de)	2004-12-16	Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
DE69301750D1 (de)	1996-04-18	Verwendung von 1-Alpha,24(R)-Dihydroxy-22(E)-Dehydrovitamin-D3 zur Herstellung eines Arzneimittels zur Behandlung der Osteoporose
DE58904328D1 (de)	1993-06-17	Verfahren zur desinfektion von medizinischen abformmassen.
DE58902128D1 (de)	1992-10-01	Verfahren zur behandlung von klaerschlamm.
ATE253728T1 (de)	2003-11-15	Pyrogen-untersuchungsverfahren
DE69006509D1 (de)	1994-03-17	Verfahren zur behandlung von häuten.
DE59103291D1 (de)	1994-11-24	Verfahren zur bekämpfung von samen- und/oder bodenbürtigen schaderregern durch saatgutbehandlung.
DE3886755D1 (de)	1994-02-10	Verfahren zur behandlung von gefässkrankheiten.
DE3781279D1 (de)	1992-09-24	Verfahren zur behandlung von blut.
DE58905010D1 (de)	1993-09-02	Verfahren zur herstellung von 5-chlor-3-chlorsulfonyl-2-thiophencarbonsaeureestern.
DE3880070D1 (de)	1993-05-13	Verfahren zur herstellung von nicht-konjugierten diolefinen.
GR1002803B (el)	1997-11-10	Μεθοδος αποφυγης της κακοσμιας που αναπτυσσεται κατα την βοστρυχωση των μαλλιων με την εφαρμογη κυστεαμινης και αλλων θειουχων ενωσεων.
DE68905602D1 (de)	1993-04-29	Verfahren zur behandlung von titanstrukturen.
DE3863762D1 (de)	1991-08-22	Verfahren zur behandlung von frischholz.